论文部分内容阅读
为观察ＣＤ３ＡＫ或肿瘤浸润的淋巴细胞（ＴＩＬ）治疗晚期癌症的效果，对６３例晚期癌症患者用效应细胞（ＣＤ３ＡＫ或ＴＩＬ，总数１５×１０９～５×１０９），联用白细胞介素２１２０万Ｕ～５００万Ｕ，进行过继免疫治疗（ＡＩＴ）。结果１８例癌性胸水患者，治疗后１４例有效，有效率７７８％；４５例实体瘤患者经ＡＩＴ治疗，４例部分缓解，１１例肿瘤体积、小转移灶或肿大淋巴结有缩小变化。此外多数患者自觉症状和免疫功能也有明显改进和提高。认为ＡＩＴ对某些晚期癌症治疗，可缩小肿瘤、提高免疫功能，如与其他疗法配合疗效更好。
To observe the efficacy of CD3AK or tumor-infiltrating lymphocytes (TIL) in the treatment of advanced cancer, 63 effector cells for advanced cancer patients (CD3AK or TIL, total number 15×109~5×109) were used together with interleukin 21.2 million U to 5 million U, adoptive immunotherapy (AIT). Results In 18 cases of cancerous pleural effusion, 14 cases were effective after treatment, with an effective rate of 77.8%; 45 cases of solid tumors were treated with AIT, 4 cases were partially relieved, and 11 cases had small changes in tumor volume, small metastases, or enlarged lymph nodes. . In addition, subjective symptoms and immune function were also significantly improved and improved in most patients. It is believed that AIT can reduce tumors and improve immune function for certain advanced cancer treatments, such as better efficacy with other therapies.